OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 9, pp. 949-958
Open Access | Times Cited: 16
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 9, pp. 949-958
Open Access | Times Cited: 16
Showing 16 citing articles:
Immune check point inhibitors for ocular adnexal and periocular tumors
Palwasha Syar, Sara Moussavi, Carlos Torres-Caballa, et al.
Taiwan Journal of Ophthalmology (2025) Vol. 15, Iss. 1, pp. 14-25
Open Access | Times Cited: 1
Palwasha Syar, Sara Moussavi, Carlos Torres-Caballa, et al.
Taiwan Journal of Ophthalmology (2025) Vol. 15, Iss. 1, pp. 14-25
Open Access | Times Cited: 1
Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors
Kaori Matsumoto, Tatsuo Kanda, Junichiro Wakatsuki, et al.
Hepatology International (2025)
Closed Access | Times Cited: 1
Kaori Matsumoto, Tatsuo Kanda, Junichiro Wakatsuki, et al.
Hepatology International (2025)
Closed Access | Times Cited: 1
Emerging roles of checkpoint molecules on B cells
Hiromitsu Asashima, Satoshi Akao, Isao Matsumoto
Immunological Medicine (2025), pp. 1-12
Open Access
Hiromitsu Asashima, Satoshi Akao, Isao Matsumoto
Immunological Medicine (2025), pp. 1-12
Open Access
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?
Andreea Paroşanu, Cornelia Nititpir, Ioana-Miruna Stanciu, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 543-543
Open Access
Andreea Paroşanu, Cornelia Nititpir, Ioana-Miruna Stanciu, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 543-543
Open Access
Antibody-Free Immunopeptide Nano-Conjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme
Saurabh Sharma, David Lee, Surjendu Maity, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Saurabh Sharma, David Lee, Surjendu Maity, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Type I Diabetes—A Rare Adverse Event Described in Patients Receiving Immunotherapy Versus a Side Effect from SARS-CoV-2 Infection
Raluca-Ileana Pătru, Miruna Ghigeanu, Maria-Alexandra Barbu, et al.
Reports — Medical Cases Images and Videos (2025) Vol. 8, Iss. 1, pp. 31-31
Open Access
Raluca-Ileana Pătru, Miruna Ghigeanu, Maria-Alexandra Barbu, et al.
Reports — Medical Cases Images and Videos (2025) Vol. 8, Iss. 1, pp. 31-31
Open Access
Correlative analysis of immune-related thyroid dysfunction and prognosis in patients with advanced esophageal squamous cell carcinoma
Liangshan Da, Ziting Qu, Yiyin Zhang, et al.
Anti-Cancer Drugs (2025)
Closed Access
Liangshan Da, Ziting Qu, Yiyin Zhang, et al.
Anti-Cancer Drugs (2025)
Closed Access
Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients
Martina Catalano, Giulia Venturi, Alessia Salfi, et al.
Immunotherapy (2025), pp. 1-10
Closed Access
Martina Catalano, Giulia Venturi, Alessia Salfi, et al.
Immunotherapy (2025), pp. 1-10
Closed Access
Plasma cytokine levels in a patient with multiple immune-mediated adverse events on the background of nivolumab therapy for metastatic skin melanoma
V. V. Khizha, D. I. Kozlova, Георгий Владимирович Шолохов, et al.
Cytokines and inflammation (2025)
Closed Access
V. V. Khizha, D. I. Kozlova, Георгий Владимирович Шолохов, et al.
Cytokines and inflammation (2025)
Closed Access
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Renata Pacholczak‐Madej, Artur Drobniak, Łukasz Stokłosa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery
Akira Torii, Natsuo Tomita, Taiki Takaoka, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 1
Akira Torii, Natsuo Tomita, Taiki Takaoka, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 1
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis
Elsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Elsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Rechallenge with immune checkpoint inhibitors therapy for patients with HCC-lot more to learn
George Lau
Hepatology International (2024)
Open Access
George Lau
Hepatology International (2024)
Open Access
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
Tianhang Zhang, Haitao Lv, J. Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Tianhang Zhang, Haitao Lv, J. Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Abdulaziz M. Eshaq, Thomas W. Flanagan, Anass Abbad, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 88-88
Open Access
Abdulaziz M. Eshaq, Thomas W. Flanagan, Anass Abbad, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 88-88
Open Access
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
Alberto Savino, A. Rossi, S. Fagiuoli, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 76-76
Open Access
Alberto Savino, A. Rossi, S. Fagiuoli, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 76-76
Open Access
